A new kidney cancer drug’s effectiveness has been over-estimated by as much as 45% because of flawed animal experiments during its development, researchers have claimed. Scientists said mistakes relating to the drug, sunitinib, called into question the way cancer therapies are tested on animals prior to patient trials.
Are you up for a challenge?
